Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. Its pipeline includes antibody-based, masked T-cell engager, and siRNA programs, with development and manufacturing activities centered in San Francisco and supported by third-party collaborators and CDMOs.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaPrograms aimed at chronic hepatitis delta, hepatitis B, HIV cure, and other serious infectious diseases.
Dual-masked T-cell engager programs targeting validated solid tumor antigens.
Earlier-stage discovery programs across infectious disease and oncology targets.
Revenue from partnered programs, licenses, grants, and research services.
Tuotteet
Raportoitu · osuus liikevaihdosta- Contract Revenue73,6 %
- Profit Sharing Amount12,1 %
- Collaboration Revenue11,2 %
- Other Revenue3,1 %
Lähde: 10-K FY2024, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Vir does not sell a broad commercial product portfolio today; its economic counterparties are primarily biopharmaceutical partners, research collaborators, and grant sponsors. If approved, its medicines would be sold to healthcare providers and reimbursed through public and private payers, with commercialization in some territories handled through partners such as Norgine or Astellas.
Partners such as GSK, Norgine, Alnylam, and Astellas that license programs, share development costs, or commercialize assets.
Organizations funding research programs, especially in infectious disease and HIV cure work.
Hospitals, specialists, and oncology/infectious disease clinicians that would prescribe approved therapies.
End users of the company’s future approved medicines, especially CHD, CHB, and solid tumor patients.
Strategia
Vir’s strategy is to advance differentiated immunology platforms into late-stage development, with emphasis on chronic hepatitis delta, hepatitis B, and masked T-cell engagers for solid tumors. It also uses partnerships to share development risk, extend commercialization reach, and access external capabilities while retaining selected rights in key markets.
Late-stage progress is needed to create approvable assets and future commercial value.
Partnering reduces funding needs and adds commercial or development expertise.
Multiple modalities can diversify scientific risk and broaden addressable markets.
Maantiede
Q3/2025Vir is headquartered in the United States, with process development and small-scale manufacturing activities at its San Francisco corporate site. Its business is global in scope because development, licensing, and commercialization rights are structured across the U.S. and ex-U.S. territories through partners.
Riskit
Vir faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory delay, and dependence on external funding and partners. Its revenue base is still largely collaboration-driven, so changes in partner behavior, trial outcomes, manufacturing execution, or reimbursement assumptions can materially affect future prospects.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Pipeline value depends on proving safety and efficacy in human trials.
Kohdistuu - Capital dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company has not yet established a meaningful commercial base and may need additional financing.
Kohdistuu - Partner concentration and contract riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Revenue and development economics depend on collaboration terms and partner decisions.
Kohdistuu - Manufacturing and CDMO executionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Biologics and siRNA programs rely on third-party suppliers and contract manufacturers.
Kohdistuu - Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Other biotech and pharma companies may reach the market first or with better therapies.
Kohdistuu: Infectious disease and oncology pipelines
Kirjanpito
Harkinnanvaraiset erätProfit-share and support-cost adjustments depend on partner data and judgment.
Vaikutus: Can cause revenue volatility and retrospective adjustments
Revenue from grants, R&D services, and clinical supply agreements may be recognized over time or at milestones.
Vaikutus: Affects timing of reported revenue
Most pipeline spending is expensed as incurred, with limited capitalization.
Vaikutus: Directly affects operating loss and comparability across periods
Acquisition-related obligations require periodic remeasurement using assumptions.
Vaikutus: Can create non-cash gains or losses
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Vor Biopharma Inc.
VOR · Biological Products, (No Diagnostic Substances)
MIRA Pharmaceuticals, Inc
MIRA · Pharmaceutical Preparations
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Gilead Sciences, Inc
GILD · Biological Products, (No Diagnostic Substances)
Gilead Sciences is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases.
Zura Bio Ltd
ZURA · Biological Products, (No Diagnostic Substances)
Zura Bio Ltd is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-based therapies for immune-mediated diseases.
Päivitetty: 24.9.2026